EP
TBPH icon

Essential Partners’s Theravance Biopharma TBPH Stock Holding History

Essential Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187 Buy
11
+9
+450% +$149 ﹤0.01% 2653
2026
Q1 		$32 Sell
2
-2
-50% -$35 ﹤0.01% 2804
2025
Q4 		$75 Buy
4
+2
+100% +$33 ﹤0.01% 2592
2025
Q3 		$29 Buy
+2
New +$25 ﹤0.01% 2615

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Essential Partners's TBPH Position: Q2 2026 in Review

Essential Partners increased its Theravance Biopharma (TBPH) stake by 450% in Q2 2026, buying an estimated $149 and bringing the position to 11 shares worth $187. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

Essential Partners first reported a position in TBPH in Q3 2025 and has held it in 4 quarters since. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Essential Partners held 11 shares of Theravance Biopharma worth $187 as of Q2 2026.
  • Essential Partners bought 9 Theravance Biopharma shares in Q2 2026, an estimated $149.
  • Theravance Biopharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2653 holding.
  • Essential Partners first reported a position in Theravance Biopharma in Q3 2025 and has held it in 4 quarters since.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.